Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Novartis taps Amazon know-how for ‘smart’ manufacturing, supply chain
Pharmaforum
Thu, 12/5/19 - 10:04 am
Tags:
Novartis, Amazon, drug manufacturing, distribution
Gene Therapy M&A Appetite Provides Lift After Audentes Deal
Yahoo/Bloomberg
Wed, 12/4/19 - 10:02 am
Tags:
gene therapy, Astellas, Audentes Therapeutics, M&A, Novartis, Medicines Company
Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen
Motley Fool
Mon, 12/2/19 - 11:59 pm
Tags:
Novartis, Medicines Company, M&A, inclisiran
Novartis opens new cell and gene therapies facility in Switzerland
Pharmaceutical Business Review
Sat, 11/30/19 - 11:14 pm
Tags:
Novartis, cell therapy, gene therapy, Switzerland
Drugs firms make massive discounts to get reimbursement in China
Pharmaforum
Fri, 11/29/19 - 02:33 pm
Tags:
Roche, Novartis, China, reimbursement
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
RAPS.org
Wed, 11/27/19 - 12:39 pm
Tags:
FDA, Vertex Pharmaceuticals, Trikafta, Novartis, Adakveo, Alnylam, Givlaari, BeiGene, Brukinsa, Global Blood Therapeutics, Oxbryta, drug approvals
Pfizer, Novartis lead $2 billion spending spree on gene therapy production
Reuters
Wed, 11/27/19 - 12:36 pm
Tags:
gene therapy, drug manufacturing, Pfizer, Novartis, Bluebird Bio, PTC Therapeutics, Krystal Biotech
Why Novartis Is Buying The Medicines Company For $9.7 Billion
Forbes
Tue, 11/26/19 - 09:44 am
Tags:
Novartis, Medicines Company, M&A, inclisiran
Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's maker
Fierce Pharma
Mon, 11/25/19 - 09:49 pm
Tags:
Amarin, M&A, Novartis, Medicines Company, Gilead Sciences
Ex-Purdue CEO stands to earn a huge windfall in Novartis' buyout of the Medicines Co
Endpoints
Mon, 11/25/19 - 09:46 pm
Tags:
Mark Timney, Purdue Pharma, Novartis, Medicines Company, M&A
Novartis buys Medicines Co. in $9.7B bet on cholesterol drug
Biopharma Dive
Sun, 11/24/19 - 11:38 pm
Tags:
Novartis, The Medicines Company, M&A
Global Blood Therapeutics Goes Head to Head With Novartis On Sickle Cell
Motley Fool
Sun, 11/24/19 - 11:26 pm
Tags:
Global Blood Therapeutics, voxelotor, Novartis, Adakveo, sickle cell disease
Which asthma biologic do docs prefer? It's not that simple: analyst
Fierce Pharma
Sat, 11/23/19 - 03:47 pm
Tags:
asthma, Roche, Novartis, Xolair, Sanofi, Regeneron, Dupixent, physicians
Patient charity to pay $4M to settle kickback allegations
Beckers Hospital Review
Fri, 11/22/19 - 10:12 am
Tags:
kickbacks, Medicare, Medicare fraud, MS, multiple sclerosis, Teva Pharmaceutical, Biogen, Novartis
Novartis, Bayer, Longwood back genomics startup to speed search for immunotherapy targets
Endpoints
Thu, 11/21/19 - 10:21 am
Tags:
Novartis, Bayer, Longwood, immunotherapy, genomics, immuno-oncology
Looking for a Biotech Stock That's an Ideal Buyout Candidate? This Is It.
Motley Fool
Wed, 11/20/19 - 10:02 am
Tags:
Amarin, Vascepa, M&A, Amgen, Novartis, Pfizer
AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so much
Fierce Pharma
Tue, 11/19/19 - 11:38 pm
Tags:
earnings, Big Pharma, AstraZeneca, Merck, Celgene, Novartis, Novo Nordisk, Pfizer
Amidst Novartis Takeover Rumors, The Medicines Company Announces Positive Cholesterol Data
BioSpace
Tue, 11/19/19 - 11:32 pm
Tags:
The Medicines Company, Novartis, M&A, inclisiran, clinical trials
Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprised
Fierce Pharma
Tue, 11/19/19 - 02:41 pm
Tags:
MS, multiple sclerosis, physicians, Novartis, Mayzent, Merck KGaA, Mavenclad, Biogen, Vumerity
Novartis eyes Medicines Co to boost cardio franchise - report
Yahoo/Reuters
Tue, 11/19/19 - 10:18 am
Tags:
Novartis, The Medicines Company, cardiovascular disease, M&A

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.